If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACC.L Regulatory News (ACC)

  • There is currently no data for ACC

Pulsar update

6 Feb 2020 07:00

RNS Number : 1294C
Access Intelligence PLC
06 February 2020
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain for the purposes of MAR.

 

 

 

6th February 2020

ACCESS INTELLIGENCE PLC

Completion of Pulsar Accounting Review

Further to the announcement on 10 December 2019, the Board of Access Intelligence provides the following update following the completion of the review by an external firm of accountants of the accounts of the Pulsar business at closing.

In October 2019, Access Intelligence acquired the Pulsar business (comprising both Fenix Media Limited, which is incorporated in the UK, and Face US, which is incorporated in the US) from Cello Health plc ("Cello"). Following the identification of certain accounting questions on some contracts within Pulsar post acquisition, the Board of Access Intelligence commissioned an accounting review to be undertaken by independent accountants BDO.

Following completion of the BDO review, an adjustment of the previously disclosed unaudited financial results for Pulsar is required. Post this adjustment, for the year to 31 December 2018 Pulsar reported unaudited revenues of £6.8 million, gross profit of £3.8 million and an Adjusted EBITDA loss of £0.7 million. Upon acquisition by Access Intelligence, Pulsar's accounting reference period was amended. For the 11 month period to 30 November 2019, Pulsar would have had reported unaudited revenue of £5.2 million, gross profit of £2.3 million and an Adjusted EBITDA loss of £1.7 million.

Pursuant to the terms of the sale and purchase agreement signed on 2 October 2019 (the "Agreement"), and under the completion accounts reconciliation process agreed by both sides, Cello Health has agreed to pay Access Intelligence a net cash sum of £1.6m reflecting the shortfall in net assets delivered at closing versus the agreed target closing position.

In full and final settlement of any dispute under the Agreement regarding the appropriate valuation of the business, Cello Health has agreed that 4,076,238 of the consideration shares will be sold back to Access Intelligence for £1. As Access Intelligence currently does not have the requisite approvals to acquire these shares, a shareholder's meeting will be convened to obtain the necessary approval for the buy back. Upon completion of the buy back the relevant shares will be cancelled.

The post-acquisition contribution of Pulsar to Access Intelligence's consolidated financial results for the year to 30 November 2019 is expected to be revenue of £0.7 million, gross profit of £0.2 million and an Adjusted EBITDA loss of £0.5 million, prior to any acquisition accounting adjustments. The annual accounts may also be impacted by a potential non-cash write down. This is currently being discussed with the accountants and an update will be provided in due course.

This outcome of the financial analysis has no impact on the rationale for the Pulsar acquisition which is in line with a strategic ambition to strengthen capabilities in social media analysis, audience segmentation and social media marketing evaluation. Recurring revenues with Pulsar are around 70% of total revenue.

Related Party Transaction

Cello is a related party of the Company for the purposes of the AIM Rules by virtue of their status as substantial shareholders holding 10% or more or more of the Company's existing ordinary share capital.

The Board consider, having consulted with the Company's nominated adviser, finnCap, that the settlement with Cello set out above is fair and reasonable insofar as the Company's shareholders are concerned.

Commenting on the resolution of this matter, Joanna Arnold, CEO, said:

"Due to Cello Health's proactive engagement, we are pleased to have reached a swift and satisfactory resolution. The rationale for the acquisition remains unchanged and we look forward to growing the business as part of the Access Intelligence portfolio."

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

 

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance - Marc Milmo / Kate Bannatyne / Matthew Radley / Kate Washington

Corporate Broking - Alice Lane / Sunila de Silva

 

About Access Intelligence

 Access Intelligence PLC is a tech innovator, delivering high quality SaaS products that address the fundamental business needs of more than 3,500 global brands in the PR, communications and marketing industries. Listed on AIM, Access Intelligence provides technology that helps organisations understand what's important to their customers and their brand as they navigate a constantly changing world of politics, news and social media. This is alongside the practical tools and information to ensure their communications are relentlessly effective in building awareness, reputation and engagement.

 The expanding portfolio includes Vuelio, the platform that helps organisations make their stories matter; ResponseSource, a network that connects media and influencers to the resources they need, fast; and Pulsar, an audience insights and social listening platform.

 

- ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURSSIEEIESSESE
Date   Source Headline
22nd Sep 20117:00 amRNSCobent Vendor Arrangements and Trading Update
22nd Aug 20114:25 pmRNSDirector/PDMR Shareholding
11th Jul 20117:00 amRNSNotice of Results
4th Jul 20117:00 amRNSSale of Solcara Limited
27th May 201112:16 pmRNSAnnual Report and Accounts
4th Apr 201112:45 pmRNSDirector/PDMR Shareholding
7th Mar 20117:00 amRNSFinal Results
31st Jan 20117:28 amRNSManagement Update
16th Dec 20107:00 amRNSTrading Update and Directorate Change
3rd Nov 20107:00 amRNSNominated adviser and broker change of name
31st Aug 20107:00 amRNSIssue of equity on conversion of Loan Notes
19th Jul 20107:00 amRNSHalf Yearly Report
23rd Jun 20107:00 amRNSNotice of Results
14th Apr 201012:55 pmRNSResult of AGM
31st Mar 20107:00 amRNSHolding(s) in Company
25th Mar 201012:08 pmRNSDirector Dealing and Exercise of Options
25th Mar 20107:50 amRNSNotice of AGM
3rd Mar 20106:26 pmRNSHolding(s) in Company
3rd Mar 20103:22 pmRNSIssue of Equity
2nd Mar 20109:06 amRNSDirector/PDMR Shareholding
1st Mar 20107:00 amRNSAcquisition
1st Mar 20107:00 amRNSPreliminary Results
23rd Feb 20107:00 amRNSNotice of results meeting
12th Jan 20107:00 amRNSTrading Statement
2nd Nov 20099:08 amRNSDirector/PDMR Shareholding
6th Oct 20098:52 amRNSIssue of Share Options
29th Jul 20091:30 pmRNSResult of General Meeting
10th Jul 20097:00 amRNSAdditional Convertible Loan Notes
1st Jul 20097:00 amRNSAcquisition and Convertible Loan Note
24th Jun 20097:00 amRNSHalf Yearly Report
15th Jun 20097:00 amRNSChange of Name of Nominated Adviser and Broker
1st May 20092:52 pmRNSResult of AGM
23rd Mar 20097:00 amRNSFinal Results
22nd Dec 20087:00 amRNSTotal Voting Rights
12th Dec 20087:00 amPRNDirectorate Change
9th Dec 20087:00 amRNSIssue of Equity
19th Nov 20087:00 amPRNShareholder Information
5th Nov 20087:01 amPRNDirectorate Change
5th Nov 20087:00 amRNSDisposal
5th Nov 20087:00 amPRNAcquisition of Solcara
31st Oct 20087:00 amPRNTotal Voting Rights
27th Oct 20087:00 amPRNDirectorate Change
20th Oct 200810:42 amPRNResult of EGM
24th Sep 20087:00 amRNSBoard Changes & Subscription
6th Aug 20087:00 amRNSInterim Results
21st Jul 20087:00 amRNSNotice of Results
6th Jun 20087:00 amRNSTrading Statement
5th Jun 20085:53 pmRNSTrading Statement
12th Mar 20087:00 amRNSChange in Shareholding
6th Mar 20087:00 amPRNFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.